MedTrace Logo

Endothelial Dysfunction in Covid-19

NCT04830683 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2021-04-09

No results posted yet for this study

Summary

SARS-CoV-2 targets endothelial cells via the angiotensin-converting enzyme 2 receptor. The specific impact of the resulting endothelial injury is currently unknown but may contribute to the pro-coagulant state classically described during Covid-19 disease and commonly associated with an exacerbated activation of the renin-angiotensin-aldosterone system.

Conditions

  • Covid19
  • Hypoxemic Respiratory Failure

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • VIRGINIE MONTIEL, MD,PhD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2021-03-25
Completion
2021-04-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830683 on ClinicalTrials.gov